Community-Acquired Pneumonia (CAP) Surveillance

Bayer560 enrolled

Overview

Prospective, non-interventional, multi-center study. 7 investigative centers will involved in China. Around 560 CAP outpatients or inpatients will be screened until 56 M. pneumoniae isolates collected.

Study Type

OBSERVATIONAL

Enrollment

560

Conditions

Pneumonia

Interventions

No DrugOTHER

It's a surveillance

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Chinese adult (male or female) ≥18 years old * Outpatients or inpatients who suffer from CAP Exclusion Criteria: \-

Locations (1)

Unnamed facility

Many Locations, China

Outcomes

Primary Outcomes

In vitro Minimal Inhibitory Concentration Detection

Time frame: Up to 27 months

Secondary Outcomes

In vitro Gene Mutation Detection

Time frame: Up to 15 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.